quinazolines has been researched along with navitoclax in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kameda, Y; Koizume, S; Matsukuma, S; Miyagi, Y; Nakamura, Y; Nakayama, H; Sakuma, Y; Yamazaki, Y; Yokose, T; Yoshihara, M | 1 |
| Del Vecchio, S; Iommelli, F; Salvatore, M; Speranza, A; Zannetti, A | 1 |
| Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Gelston, E; Liu, A; Liu, Q; Wang, B; Wang, H; Wu, X; Xu, J; Xu, L; Zeng, Y; Zhou, W; Zou, Z | 1 |
| He, W; Huang, S; Ji, D; Lan, H; Li, L; Li, Z; Liu, X; Wang, Y; Wu, Z; Xu, J; Yang, F; Zhang, W; Zhou, W | 1 |
| Di, W; Jing, Y; Ma, P; Wang, X; Yin, X; Zhang, M; Zhang, S; Zhang, Z; Zhuang, G | 1 |
| Akudugu, JM; Hamid, MB; Serafin, AM | 1 |
8 other study(ies) available for quinazolines and navitoclax
| Article | Year |
|---|---|
WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
Topics: Acrylamides; Adenocarcinoma; Aged; Aged, 80 and over; Aniline Compounds; Anoikis; Benzodioxoles; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; src-Family Kinases; Sulfonamides | 2012 |
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Mice, Inbred BALB C; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Sulfonamides; Tomography, X-Ray Computed | 2012 |
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells.
Topics: Aniline Compounds; Apoptosis; bcl-X Protein; Benzamides; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Indoles; Leukemia, Myeloid, Acute; Mitosis; Oxindoles; Phosphorylation; Polyploidy; Quinazolines; RNA, Small Interfering; Sulfonamides; U937 Cells; Vinblastine | 2015 |
CyclinG1 Amplification Enhances Aurora Kinase Inhibitor-Induced Polyploid Resistance and Inhibition of Bcl-2 Pathway Reverses the Resistance.
Topics: Adult; Aniline Compounds; Antineoplastic Agents, Phytogenic; bcl-X Protein; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin G1; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Polyploidy; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; Sulfonamides; Triple Negative Breast Neoplasms | 2017 |
Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors.
Topics: Aniline Compounds; Animals; bcl-X Protein; Benzylamines; Cell Line, Tumor; CRISPR-Cas Systems; Endopeptidases; HEK293 Cells; Humans; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; Sulfonamides; Ubiquitin-Specific Proteases; Ubiquitination; Xenograft Model Antitumor Assays | 2018 |
Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells.
Topics: Aniline Compounds; Breast Neoplasms; Cell Line; Cell Survival; ErbB Receptors; Female; Humans; Imidazoles; Lung Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Quinolines; Radiation Tolerance; Sulfonamides; TOR Serine-Threonine Kinases; Tyrphostins; Uterine Cervical Neoplasms; X-Rays | 2021 |